Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.

[1]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[2]  J. Cashy,et al.  Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  C. Gross,et al.  Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities , 2007, Annals of Surgical Oncology.

[4]  S. Chevret,et al.  Factors influencing inclusion of patients with malignancies in clinical trials , 2006, Cancer.

[5]  Michelle A. Mathiason,et al.  Clinical trial accrual among new cancer patients at a community‐based cancer center , 2006, Cancer.

[6]  A. Giuliano,et al.  A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. , 2004, Journal of the American College of Surgeons.

[7]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[9]  P. Philip,et al.  Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Cook,et al.  Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review , 2004, The Lancet.

[11]  G. Pond,et al.  Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Fey,et al.  Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[14]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Michael A. Gold,et al.  Impact of Individual Physicians on Enrollment of Patients into Clinical Trials , 2003, American journal of clinical oncology.

[16]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Bunn,et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer. , 2003, Journal of the National Cancer Institute.

[18]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Gandara,et al.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[21]  V. Cottin,et al.  Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Coebergh,et al.  Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. , 1998, Lung cancer.

[23]  E. Trimble,et al.  Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. , 1996, Journal of the National Cancer Institute.

[24]  W Wood,et al.  Selection bias in clinical trials. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.